BioSpace News Archive

Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.

LAVA Therapeutics is now financially poised to advance their bispecific antibodies to engage Vγ9Vδ2 T cells in the fight against cancer thanks to an infusion of capital from an oversubscribed $83 million Series C financing.

It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.

Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.

Biotech needs to get tougher on pipeline decisions, according to BDO’s recently released annual Biotech Briefing.

85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.

Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.

Successfully completed IPO in August 2020 raising $76.6 million in gross proceeds On track to initiate planned new clinical trials in melanoma and head and neck cancer

Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.

PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with IMFINZI® had not progressed after four years